AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma	pancreatic ductal adenocarcinoma	Recruiting	Not stated	2026-07-23		NCT06320717

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Roswell Park Cancer Institute	92

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Good Samaritan University Hospital	West Islip	United States	30
Roswell Park Comprehensive Cancer Center	Buffalo	United States	63

Clinical trials